CASI Pharmaceuticals, Inc. (CASI) - Utang jangka dawa marang modal

CASI Pharmaceuticals is scaling its presence in China by licensing Western drugs, thereby minimizing primary testing costs. The strategy is based on organic pipeline development without active M&A transactions. The specifics of onco-hematology guarantee crisis resilience and an absence of seasonality. The value of 0.00 fixes the metric level, and the GURU.Markets service provides this long-term debt-to-capital ratio for credit risk analysis.

CASI Pharmaceuticals' expertise in launching oncology drugs into the US and Chinese markets requires significant investment in high-cost human capital. This ratio compares loans with a maturity of over one year to equity, measuring the extent to which development depends on borrowed funds. The metric determines the stability of the financial structure and the risk of a freeze in expansion. Daily updates of the long-term debt-to-equity ratio allow for the prompt diagnosis of liability stagnation. By analyzing this chart, an investor assesses default protection while maintaining growth rates.